Share Twitter LinkedIn Facebook Email Tsering Lama Tamang, M.D. Division of Hematology and Oncology, University of California, Irvine Discusses ALLIANCE Trial & Its Effect On Clinicians. At MOASC on Jan 19, 2019.
FDA Approves Adcetris / brentuximab vedotin + lenalidomide & rituximab in relapsed or refractory LBCL: Could This Change Standard Care? Lymphoma 2 Mins Read
2024 Update on Lymphoma Treatment: Navigating the Latest Advances – Elizabeth Brem, MD [38 Slides] Hodgkin Lymphoma 4 Mins Read
FDA Grants Accelerated Approval to Zanubrutinib (Brukinsa) for Relapsed or Refractory Follicular Lymphoma Lymphoma 2 Mins Read